A new study suggests that the COVID-19 vaccine produced by Moderna Inc and Pfizer-BioNtech was found 90% effective in preventing the virus in real-world conditions.
The study released on March 29, was published by the Centers for Disease Control and Prevention in its online journal Morbidity and Mortality Weekly Report.
The research that began from December 14, 2020, to March 13, 2021, involved 40,000 health workers and front-line workers in the United States. The volunteers were tested weekly for any COVID infections, even those who did not show any symptoms.
Over 62% of the volunteers had received both doses of either Pfizer or Moderna Vaccine and 12% had received only a single shot of the vaccine.
As per the findings, the real-world efficacy was found to be 80% when a single dose of vaccine was administered. And the efficacy further increased to 90% when both the doses of vaccines were administered.
Amongst the unvaccinated lot -161 were detected with the virus, amongst the volunteers who received only one dose – 12 were detected with the virus, and only 3 were detected with the virus who had received both the doses and were two weeks out from their second dose.
This study complements the results of the clinical trials that showed 95% efficacy of the Pfizer and Moderna vaccines.
“These interim vaccine effectiveness findings for both Pfizer-BioNTech’s and Moderna’s mRNA vaccines in real-world conditions complement and expand upon the vaccine effectiveness estimates from other recent studies and demonstrate that current vaccination efforts are resulting in substantial preventive benefits among working-age adults,” the study noted.
58% of the infections were detected because volunteers were tested weekly and 42% of the infections were detected after the development of symptoms. Amongst the covid positive volunteers – 10.7% had no symptoms, 23% needed medical care and 2 were hospitalized. There was no COVID-related death in the study.